trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary artery disease.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
5 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary artery disease?

Yes. Current clinical and epidemiological evidence supports the view that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary artery disease and cardiovascular events, though benefits can vary by dose and patient population.

Verdict: SUPPORTED · 5 sources for, 0 against · Last checked

The analysis

Multiple recent reviews, cohort analyses, and clinical studies (e.g., [0], [3], [6], [9], [11]) consistently report that higher intake or circulating levels of EPA and DHA are associated with reduced cardiovascular disease risk, lower mortality, and favorable changes in lipid and inflammatory profiles. While some high-dose regimens carry a trade-off regarding atrial fibrillation risk, the general finding that omega-3 consumption is protective against coronary artery disease is well-supported in the literature.

Evidence for · 5
N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health - Updated Review of Mechanisms and Clinical Outcomes.
2025
Synthesizes updated cohort data and meta-analyses consistently linking higher intake or circulating levels of EPA and DHA to a reduced risk of cardiovascular events.
Get citation
I, D. & PC, C. (2025). N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health - Updated Review of Mechanisms and Clinical Outcomes.. doi.org. https://doi.org/10.1007/s11883-025-01363-2

See more details
More for · 4
Fish oil supplements in patients with chronic kidney disease.
2026
Discusses trials reporting large reductions in cardiovascular events and mortality with fish oil supplementation containing EPA and DHA.
Get citation
CJ, F., MR, T., S, K., D, C., & JN, T. (2026). Fish oil supplements in patients with chronic kidney disease.. doi.org. https://doi.org/10.1093/ckj/sfag168

Association of Higher Dietary Omega-3 Fatty Acid Intake With Cardiovascular-Kidney-Metabolic Syndrome Stage Severity and Mortality in US Adults: A Cross-Sectional and Prospective Cohort Analysis of NHANES 1999 to 2018.
2026
Demonstrates that higher dietary n-3 PUFA intake is associated with less severe CKM stages and lower mortality risk in a threshold-dependent manner.
Get citation
LL, Z., XG, Z., J, C., P, N., JC, S., Z, Z., YX, Z., R, Q., & LC, C. (2026). Association of Higher Dietary Omega-3 Fatty Acid Intake With Cardiovascular-Kidney-Metabolic Syndrome Stage Severity and Mortality in US Adults: A Cross-Sectional and Prospective Cohort Analysis of NHANES 1999 to 2018.. doi.org. https://doi.org/10.1161/jaha.125.046079

The mediating effect of DHA-mediated MPV improvement on coronary artery stenosis and its prognostic value.
2026
Finds that DHA is an independent protective factor against major adverse cardiovascular events and correlates with coronary stenosis severity.
Get citation
W, W., C, O., J, L., D, L., J, W., Y, X., B, L., Y, L., Y, H., & J, W. (2026). The mediating effect of DHA-mediated MPV improvement on coronary artery stenosis and its prognostic value.. doi.org. https://doi.org/10.3389/fcvm.2026.1809653

Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability.
2026
Notes that omega-3 fatty acids act through beneficial mechanisms, with high-dose purified EPA demonstrating substantial reductions in cardiovascular risk.
Get citation
F, E., E, R., M, G., A, N., & V, D. G. (2026). Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability.. doi.org. https://doi.org/10.3390/nu18152538

What does the evidence say?

Multiple recent reviews, cohort analyses, and clinical studies (e.g., [0], [3], [6], [9], [11]) consistently report that higher intake or circulating levels of EPA and DHA are associated with reduced cardiovascular disease risk, lower mortality, and favorable changes in lipid and inflammatory profiles. While some high-dose regimens carry a trade-off regarding atrial fibrillation risk, the general finding that omega-3 consumption is protective against coronary artery disease is well-supported in the literature.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work